BioSector-2 is a forward-thinking biotechnology company headquartered in Cambridge, MA, dedicated to the discovery, development, and commercialization of novel therapeutics for critical unmet medical needs. Our research focuses on leveraging cutting-edge science in areas such as genetic medicine, immunology, and protein engineering to create transformative treatments. At BioSector-2, we are driven by a passion for science and a commitment to improving patient lives globally.
The Cambridge headquarters serves as the central hub for executive leadership, research and development (R&D) laboratories, bioinformatics, corporate strategy, business development, and administrative functions.
Features advanced R&D laboratories equipped with state-of-the-art instrumentation, collaborative open-plan office spaces designed to foster innovation, and environmentally conscious building design.
BioSector-2 cultivates a dynamic and inclusive work culture characterized by scientific rigor, collaboration, agility, and a strong sense of purpose. Employees are encouraged to be innovative and are empowered to contribute to meaningful scientific advancements.
Its location in Kendall Square provides unparalleled access to a rich ecosystem of world-class academic institutions (like MIT and Harvard), leading research hospitals, a highly skilled talent pool, and a vibrant venture capital community, fostering collaboration and growth.
BioSector-2 maintains a significant presence in North America with its headquarters in Cambridge, MA, and a key office in San Diego, CA. Its European operations are managed from Zug, Switzerland. Globally, the company supports its research and clinical development programs through collaborations with international academic institutions, contract research organizations (CROs), and contract manufacturing organizations (CMOs) across multiple continents. This distributed model allows for efficient execution of global clinical trials and access to specialized expertise worldwide.
750 Kendall Square, Suite 300
Cambridge
MA
USA
Address: 101 Biotech Avenue, San Diego, CA 92121
Serves as a key site for managing West Coast clinical trials, fostering collaborations with Pacific Rim partners, and engaging with the vibrant biotech community in Southern California.
Address: Alpenstrasse 15, 6300 Zug, Switzerland
Manages European Union (EU) and Swiss regulatory submissions, coordinates with European health authorities, and prepares for potential commercial launches in Europe.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Biosector 2' leadership includes:
Biosector 2 has been backed by several prominent investors over the years, including:
Over the past 12 months, BioSector-2 has strategically strengthened its executive team with a key appointment to bolster its operational capabilities, and experienced one planned leadership transition.
Discover the tools Biosector 2 uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
BioSector-2 typically utilizes a standard email format of [first_initial][last_name]@[domain]. For example, Jane Doe would be jdoe@biosector-2-hypothetical.com. Another common format is [first_name].[last_name]@[domain].
flast@biosector-2-hypothetical.com (e.g., ereed@biosector-2-hypothetical.com) or first.last@biosector-2-hypothetical.com (e.g., evelyn.reed@biosector-2-hypothetical.com)
Format
ereed@biosector-2-hypothetical.com
Example
90%
Success rate
FierceBiotech (Hypothetical) • March 15, 2024
BioSector-2 announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 3 clinical trial for its lead investigational therapy, BS2-101, for the treatment of relapsed/refractory lymphoma. The decision follows a successful End-of-Phase 2 meeting with the agency....more
BioCentury (Hypothetical) • January 22, 2024
BioSector-2 and Pharmaco Inc. have entered into a multi-year strategic research collaboration and license agreement to discover and develop novel gene therapies for rare genetic disorders. BioSector-2 will receive an upfront payment and is eligible for research, development, and commercial milestones, plus royalties....more
Endpoints News (Hypothetical) • September 05, 2023
To accommodate its growing pipeline and research teams, BioSector-2 today announced the opening of a new 80,000 square foot research and development facility in Kendall Square, Cambridge, further solidifying its presence in the leading biotech hub....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Biosector 2, are just a search away.